Job openings on the Paratek Pharmaceuticals team are listed below along with a downloadable description of each position. Click the job title to learn more about the position. Apply for a position at Paratek Pharmaceuticals today >>
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.
Paratek's lead candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.
Omadacycline is a new, once-daily, oral and IV, well-tolerated, broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community acquired bacterial pneumonia (CABP), urinary tract infections (UTI), and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern.
The Food and Drug Administration (FDA) granted omadacycline a Qualified Infectious Disease Product (QIDP) designation and completed two special protocol assessments for its Phase 3 clinical trial program.
Our second Phase 3 product candidate, sarecycline, is a new, once-daily, oral tetracycline-derived compound for the potential treatment of acne and rosacea in the community setting. Sarecycline was designed to be a well-tolerated, once-daily, oral, narrow spectrum antibiotic with anti-inflammatory properties. Paratek has licensed the U.S. rights to Allergan for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights.